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Thiazolidinediones are a class of Peroxisome Proliferator Activated Receptor γ (PPARγ) agonists that reduce insulin resistance in
type 2 diabetic patients. Although no detectable hepatic toxicity has been evidenced in animal studies during preclinical trials,
these molecules have nevertheless induced hepatic adverse eﬀects in some treated patients. The mechanism(s) of hepatotoxicity
remains equivocal. Several studies have been conducted using PCR analysis and microarray technology to identify possible target
genes and here we review the data obtained from various in vivo and in vitro experimental models. Although PPARγ is expressed
at a much lower level in liver than in adipose tissue, PPARγ agonists exert various PPARγ-dependent eﬀects in liver in addition to
PPARγ-independent eﬀects. Diﬀerences in eﬀects are dependent on the choice of agonist and experimental conditions in rodent
animal studies and in rodent and human liver cell cultures. These eﬀects are much more pronounced in obese and diabetic liver.
Moreover, our own recent studies have shown major interindividual variability in the response of primary human hepatocyte
populations to troglitazone treatment, supporting the occurrence of hepatotoxicity in only some individuals.
1.Introduction
Obesity has emerged as a major health problem with 1.6 bil-
lion adults classiﬁed as overweight and obese. The condition
is associated with type 2 diabetes, cardiovascular diseases,
and several cancers [1] and is characterized by an increase in
the size and number of adipocytes. Peroxisome proliferator-
activated receptors (PPARs) act as lipid sensors and therefore
represent critical molecular targets for the treatment of
obesity. Thus, agonists of peroxisome proliferator-activated
receptor γ (PPARγ, also known as NR1C3) are used
to treat non-insulin-dependent diabetes type 2. PPARγ
belongs to the superfamily of nuclear receptors; it acts as
a critical transcription factor in the regulation of adipose
diﬀerentiation, lipid storage, and of genes involved in energy
storage and utilisation. One putative mechanism through
which PPARγ enhances insulin sensitivity is its ability to
channel fatty acids into adipose tissue, thus decreasing
plasma fatty acid concentration. PPARγ can also aﬀect
insulin sensitivity by regulating hormones, cytokines, and
proteins that are involved in insulin resistance [2]. It exists as
two forms encoded by multiple transcript variants. PPARγ1
is the predominant isoform in humans; it is highly expressed
in adipose tissue but is also expressed in many other cell
types in which it plays important functions, particularly
intestine and immune cells. PPARγ1 is the main isoform
found in liver. PPARγ2 is found at high levels in diﬀerent
adipose tissues [3]. Hepatic PPARγ represents only 10–30%2 PPAR Research
of the level in adipose tissue [4]. The PPAR superfamily
contains two other subtypes, PPARα (NR1C1) and PPARβ/δ
(NR1C2). PPARα is highly expressed in liver, kidney, small
intestine, heart, and muscle, and it involved in fatty acid
catabolism. PPARβ/δ is ubiquitous; although less studied, it
is also implicated in fatty acid oxidation [5].
The mechanisms of action of PPARs have been well
studied. Following activation by their ligands and het-
erodimerisation with retinoid X receptor (RXR), PPARs
undergo speciﬁc conformational changes that release core-
pressors (as NcoR2/SMRT) and allow for the recruitment
of coactivators (as SRC1/NCoA1, TIF2/SRC2, CBP/P300,
steroid receptor coactivator 1, RIP140 (receptor interacting
protein 140), PPARγ co-activator-1) [6–8]. PPARs then
interact with the peroxisome proliferator element (PPRE) in
the promoter region of their target genes involved in lipid
catabolism,fattyacidtransport,andglucosehomeostasis[9].
Their diﬀerential eﬀects could be explained by the cell and
promoter context as well as the availability of cofactors but
also by the speciﬁc conformation changes of the receptor
induced by each PPARγ ligand that leads to diﬀerential
promoter activation and chromatin remodelling of target
genes [10].
A wide variety of natural and synthetic PPARγ ligands
have been identiﬁed. Besides natural ligands such as 15-
deoxy-prostaglandin J2, a metabolite of prostaglandin D2
andvitaminE,PPARγ agonistsincludeseveralsyntheticdrug
classes such as glitazones and tyrosine analogs. Thiazolidine-
diones (TZDs) are a class of PPARγ agonists used in clinical
practice to reduce plasma glucose level in type 2 diabetic
patients. The adipose tissue is required for these agonists
to exert their antidiabetic but not their lipidomic eﬀects
[11]. TZDs of the ﬁrst generation were found to be highly
hepatotoxic; the ﬁrst one, ciglitazone (CIG), was abandoned
after clinical trials and the second, troglitazone (TRO), was
rapidly withdrawn from the market after reports of severe
liver failure and death [12]. A second generation of PPARγ
agonists, rosiglitazone (ROSI) and pioglitazone (PIO), has
been approved by the Food and Drug Administration (FDA)
in 1999. Hepatic failures have also been observed after
administrationofthesetwoTZDsbuttheywerelessfrequent
and severe [12]. The antidiabetic activities of another class
of PPARγ agonists, referred as tyrosine analogs, such as
GW1929 and GW7845, looked promising but none of these
compounds has been released on the market as yet [13].
S i n c ed u a lP P A R α and PPARγ agonists might provide
broader beneﬁcial metabolic eﬀects through a simultaneous
treatment of hyperglycemia and dyslipidemia, compounds
targeting both PPARα and γ have been developed by the
pharmaceutical industry. However, the ﬁrst dual agonists,
muraglitazar and tesaglitazar, have been stopped during
clinical trials due to cardiac and renal side-eﬀects, respec-
tively [14]. Other molecules are still under development, for
example,drugsbelongingtoanewclasscalledselectivePPAR
modulators (SPPARM) for the reduction of the side-eﬀects
found with glitazones, such as oedema and weight gain [15].
A major concern in the development of novel PPARγ
agonists that diﬀer from the current therapeutics is their
implication in tumor development in diﬀerent tissues.
Although, whether their activation promotes or limits this
process remains unclear and may depend on speciﬁc con-
ditions [16], the FDA requires 2-year carcinogenesis studies
in rodents of new agonists prior to the commencement of
clinical trials exceeding 6 months.
Major species diﬀerences exist in the sensitivity to TRO.
During preclinical trials, TRO did not induce detectable
hepatic toxicity in animals, including monkeys, which show
similar metabolic proﬁles to humans [17], supporting the
viewthatglitazonetoxicityisrestrictedtohumanindividuals
having a particular phenotype. Consequently, it could be
postulated that the use of human liver cell models represents
a more suitable approach than the use of their animal
counterparts for investigations of hepatotoxic eﬀects of
PPARγ agonists.
Microarray technology represents a powerful tool to
better understand the mechanisms of drug toxicity since it
permits the identiﬁcation of gene sets that are preferentially
modulatedaftertreatment.Severalinvivoandinvitrostudies
have already been published on the eﬀects of PPAR agonists
on gene expression using diﬀerent experimental conditions.
However, they mainly concern PPARα agonists [18–22].
Studies on PPARγ agonists are limited and are usually
focused on nonhepatic tissues, especially adipose tissue. We
review here the eﬀects of PPARγ agonists on hepatic gene
expression described in the literature using either in vivo
animalmodelsorinvitroanimalandhumanlivercellmodels
and make comparison with our own recent data obtained
with human hepatocyte cultures.
2.In Vivo AnimalStudies
2.1. Eﬀects of PPARγ Agonists in Normal Liver. Little infor-
mation exists on gene proﬁling changes induced by PPARγ
agonists in the liver of normal animals (Table 1); this might
be explained by the low expression of this receptor in this
organ.MoststudiesrelatetoPPARαagonisteﬀects.However,
a comparison of transcriptomic proﬁles of ROSI with six
PPARα agonists has clearly shown that this glitazone does
not signiﬁcantly regulate any of the PPARα target genes
in Sprague-Dawley rat liver [23]. In this study, Cyp4a10, a
cytochrome P450 involved in lipid metabolism, was induced
14-fold by Wy-14643 (one of the most potent PPARα ago-
nists) and only 1.5-fold by ROSI. According to Memon et al.
[24], the inability of TZDs to induce few PPARα-responsive
genes, such as the carnitine palmitoyltransferase gene (Cpt-
I), suggests that they may require the presence of other
coactivators or may be under dominant regulatory control
of other transcription factors. However, DeLuca et al. [25]
demonstrated that TZDs induce acetyl CoA oxidase (Aco)
and fatty acid binding protein 1 (Fabp1), which are known
as PPARα target genes in both wild type and PPARα null
mice,withoutanyincreaseofPPARγ expression. In addition,
it should be noted that Brun et al. [26]h a v eo b s e r v e d
some degree of cross-activation between PPARγ and PPARα
with respect to the transcription of adipocyte diﬀerentiation
genes, suggesting that residual PPARγ receptor expressed in
liver may be suﬃcient to mimicking PPARα function.PPAR Research 3
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Although preclinical animal studies have not allowed the
prediction of glitazone hepatotoxicity in humans, several
studies in animals have dealt with the mechanisms of TZDs
hepatotoxicity. A role of Cyp 3a1 has been advanced for the
enhanced acetaminophen toxicity in rats when this com-
pound is administered with TRO [38]. However, chemical
inhibition of drug metabolizing enzymes involved in TRO
metabolism did not protect against TRO-induced toxicity.
Another mechanism of toxicity could be the inhibition of
the activity of the bile salt export pump (BSEP or ABCB11),
which is responsible for cholestasis [39]. However, TRO acts
largely through the induction of apoptosis and the more
likely mechanism is via eﬀects on mitochondria resulting in
the depletion of ATP and the release of cytochrome c [40].
Interestingly, it has been recently shown that in a speciﬁc
mouse model Sod2+/− (whose mitochondrial antioxidant
defense is slightly compromised), low repeated doses of
TRO resulted in an oxidant injury to liver mitochondria,
giving further support to mitochondria as targets for
TRO-induced liver injury [41]. Nevertheless, any of the
eﬀects could explain the initiating mechanism. TZDs also
haveanti-inﬂammatoryproperties.Theyinhibitmacrophage
activation and down-regulate proinﬂammatory cytokines
such as tumor necrosis factor alpha (TNF-α) and inter-
leukin 6 (IL-6) in the liver of liposaccharide-stimulated mice
[42, 43].
2.2. Eﬀects of PPARγ Agonists in Obese and Diabetic Liver.
Several studies have dealt with the eﬀects of PPARγ agonists
in obese and diabetic mouse liver. Enhanced levels of PPARγ
have been observed in the fatty liver of several animal models
of obesity and diabetes, including ob/ob, db/db, A-Zip, and
KKAγ mice [24, 29, 32]. Thus, KKAγ and ob/ob mice exhibit
8- and 6-fold more hepatic PPARγ transcripts than C57BL/6
mice [32]. This increase was more pronounced compared to
that of PPARα mRNAs. On the contrary, Burant et al. [31]
s h o w e da2 5 %r e d u c t i o ni nP P A R γ mRNA levels after TRO
treatment of wild type animals.
The mechanistic relationship between steatosis and the
increase of PPARγ expression in the liver is still unclear. It
is possible that elevated PPARγ expression in ob/ob livers
appears to be a pathophysiological response to the severity
state of obesity and diabetes. In this regard, transcriptional
eﬀects of TZDs on their target genes have been shown to
be exacerbated in obese diabetic versus lean control animals.
Indeed, some genes were overexpressed in obese and diabetic
mice compared to controls after treatment with TRO; for
example,adipocytefattyacidbindingprotein(Ap2orFabp4)
and fatty acid translocase (Fat or Cd36) and others were
increased only in the liver of ob/ob mice, for example,
the uncoupling protein 2 gene (Ucp2) [24]. The fact that
PPARγ target genes such as Cd36 were also induced by
TRO treatment in lean mice without induction of PPARγ
expression [24] suggests that glitazone eﬀects in obese or
diabetic rodent models are diﬀerent from those occurring
in lean control animals. Therefore, it is essential to estimate
glitazone eﬀects in regard to the metabolic status of the
animals.Noteworthy,thegenesfoundtobemodulatedinthe
liver afterglitazone treatmentwereunchanged in the adipose
tissue [24].
Some diﬀerences have been observed among glitazone
eﬀects. Thus, only ROSI was found to induce an increase
of both liver weight and hepatic triglycerides in AZIP/F1
mice. This could be explained by PPARγ-independent
mechanism eﬀects [11]. However, another explanation is
the higher aﬃnity of ROSI than TRO for the PPARγ
receptor. Indeed, ROSI caused higher incidence and severity
of microvesicular steatosis in obese KKAγ mice compared to
TRO due to its higher receptor aﬃnity (approximately 100-
fold) and its higher transcriptional response. In that study,
the hepatic triglycerides content of treated and untreated
animals was not diﬀerent, leading to the conclusion that
this microvesicular steatosis is not due to triglyceride accu-
mulation. Exacerbation of fatty liver has also been reported
with ROSI which exerted its eﬀects on serum glucose levels
independently of hepatic PPARγ levels [44]. Compared to
wild type ob/ob mice, triglyceride content as well as mRNA
levels of lipogenic genes, such as fatty acid synthase (Fasn),
acetyl CoA carboxylase (Acc), and stearoyl CoA desaturase
1 (Scd1), were strongly decreased in corresponding PPARγ-
deﬁcient animals [44]. These data indicate that obese mice
are more sensitive to the steatogenic eﬀects of glitazones than
lean animals.
It has been shown that a few PPARα target genes,
such as Aco which is involved in peroxisomal β-oxidation,
were deregulated in diabetic rodent models after TZDs
treatment. Since PPARα and PPARγ recognize similar DNA
response elements, it is quite conceivable that TZDs could
modulate PPARα responsive genes in liver of obese mice
[45]. In wild type rodents, TRO and ROSI cause a decrease
in serum cholesterol, triglycerides, free fatty acid content
and, obviously, glucose levels without modifying liver or
body weight [11, 23, 31]. Their eﬀects on these biological
parameters are substantially higher in obese mice.
To understand the eﬀects of increased PPARγ expression
in fatty liver cells, Yu et al. used PPARα−/− mice and
explored gene eﬀects of PPARγ1 overexpression [27, 28].
Expression of genes involved in adipocyte diﬀerentiation
and lipid metabolism was modulated in the liver of this
KO mouse model. Noticeable increase was observed in
Cd36, glucokinase (Gk), malic enzyme (Me), low-density
lipoprotein (Ldl), microsomal transfer protein (Mtp), and
angiopoietin-like 4 (Angptl4) in the absence of any change
in CCAAT/enhancer binding protein alpha (C/ebpα), sterol
regulatory element binding protein 1 (Srebp1), phospho-
enolpyruvate carboxykinase (Pepck), and glucose trans-
porter type 2 (Glut-2 or Slc2a2) expression levels, leading to
the conclusion that there is an adipogenic conversion of the
liver when PPARγ1 is overexpressed in this organ. Moreover,
Vidal-Puig and coworkers demonstrated that forced expres-
sion of PPARγ2o rγ1 in ﬁbroblasts was suﬃcient to drive the
determination of an adipocyte cellular lineage [46]. Further-
more,therelativeabundanceofPPARαinnormallivermight
serve as a key regulator of fatty acid catabolism, thereby min-
imizing the need for pathological adipogenic transformation
ofhepatocytestostorelipids. PPARαandfattyacidoxidation
activity might partially protect from too high PPARγ1PPAR Research 7
adipogenic activity in the liver. Way et al. analyzed transcript
levels of genes involved in lipid and glucose homeostasis
in Zucker Diabetic Fatty (ZDF) rats and concluded that
PPARγ activation had coordinate eﬀects on genes involved
in important hepatic metabolic pathways such as Pepck
and glucose 6 phosphatase (G6P) which were decreased
[30].
2.3. Extrahepatic Eﬀects of PPARγ Agonists. Marked tissue-
diﬀerencesareobservedintheresponsetoglitazones:relative
to the liver and the skeletal muscle, PPARγ is 10- to
30-fold higher expressed in human and rodent adipose
tissues [47]. Likewise, while PPARγ agonists aﬀect only
a small number of genes in the liver and the skeletal
muscle, they cause conspicuous changes in gene expression
in adipose tissues [30]. Thus, following a 14-day treat-
ment of ZDF rats, ROSI decreased Tnf-α and increased
glucose transporter 4 (Glut4), muscle carnitine palmitoyl-
transferase (Cat), stearoyl CoA desaturase (SCoA), and
fatty acid translocase (Fat) in adipose tissue, while only
Fat was slightly augmented in the liver which expresses
very little hepatic PPARγ. Comparison with the eﬀects of
retinoidXreceptor-selectiveagonists,suchasLG100268,that
also produce insulin sensitization in diabetic rats, showed
that these agonists modulated diﬀerent gene patterns from
those observed with ROSI, indicating that these compounds
may act by independent and tissue-speciﬁc mechanisms
[48].
Similar tissue-diﬀerences were observed in diabetic
(db/db) mice treated with PIO for 2 weeks. Analysis of 42
genes associated with diabetes by RT q-PCR showed that
in the liver, expression of Gk, Glut-2, apolipoprotein A-
IV (ApoA-IV), PPARγ, and a series of fatty acid oxidation
enzymes were increased while those of triglyceride lipase,
lipoprotein lipase, apolipoprotein A-I (Apo-AI), and insulin
r e c e p t o rs u b s t r a t e2( I r s - 2 )w e r ed e c r e a s e d[ 49].
Glitazones decrease glucose concentrations not only by
their action on adipocytes but also by their eﬀects on the
liver and muscle. Indeed in aP2/DTA mice, whose white and
brown fat is virtually eliminated by fat-speciﬁc expression
of diphterin toxin A chain, TRO alleviated hyperglycemia
without aﬀecting PPARγ levels in liver, suggesting inde-
pendence from both adipose tissue and PPARγ receptor
[31]. However, conﬂicting observations have been reported.
Thus, after mouse treatment with PIO, gene expression
of Pepck was found to be increased in the liver by Hof-
mann et al. [50] but only in muscle by Suzuki et al.
[49]. Accordingly, increased expression of PPARγ in the
liver of diabetic mice has been reported in certain studies
[46].
PPARγ1o rγ2m R N Al e v e l sa r en o ta ﬀected in adipose
tissue by obesity in the ob/ob and Gold ThioGlucose (GTG)
animal models. Accordingly, Auboeuf et al. [51]d e m o n -
strated that obesity and non-insulin-dependent diabetes
mellitus are not associated with alteration in PPARγ gene
expression in adipose tissue in humans. However, conﬂicting
observations have been made. Indeed, Vidal-Puig et al. [46]
showed that expression of PPARγ2 mRNA is increased in
adipose tissueofobesemenandwomen,andthattheratioof
PPARγ2/γ1 is directly correlated with their body mass index.
In addition, they did not observe similar changes in muscle.
Besides its well-known function in adipocyte diﬀer-
entiation, PPARγ activation by TZDs leads to an anti-
inﬂammatory response in adipose tissue. This has been
observed in fat deposits of various obese or diabetic rodent
models [52] and in fat biopsies of type 2 diabetic patients
[53]. This anti-inﬂammatory response can be assessed by the
inhibition of expression and/or biological activity of several
p r o i n ﬂ a m m a t o r yf a c t o r ss u c ha sT N F α, IL-6, plasminogen
activator inhibitor 1 (PAI-1), monocyte chemoattractant
protein 1 (MCP-1), and angiotensinogen [54]. Proposed
molecular mechanisms, underlying this eﬀect, include inhi-
bition of the intracellular NF-kappaB pathway [55]a n da c t i -
vationofnucleartranslocationoftheglucocorticoidreceptor
[56].
Macrophages accumulate in adipose tissue of obese
animals, where they can produce inﬂammatory mediators,
contributing by this way to insulin resistance [57]. Targeted
deletion of PPARγ in macrophages severely impaired TZDs
response in mice submitted to a high fat diet [58]. These
data emphasize the crucial role of macrophages for obtaining
full eﬀects of TZDs in the context of insulin resistance or in
diabetic conditions.
Despite its weak expression level, PPARγ is thought
to play a role as a regulator of insulin action in the
skeletal muscle [59]. Indeed, it has recently been shown
thatmuscle-speciﬁc PPARγ deletion in mouse caused insulin
resistance [60]. PIO treatment of a murine model of
myoblasts, the C2C12 cells, improved insulin sensitivity
as assessed by increased glucose uptake [61]. Moreover,
some data indicate that PPARγ activation in skeletal muscle
could contribute to the beneﬁcial eﬀect of TZDs. Indeed,
experiments on myocyte models have shown that ROSI
induced local expression of the insulin-sensitizing hor-
mone adiponectin [62]. However, conﬂicting results on
the role of PPARγ in muscle have also been published,
showing that muscle speciﬁc PPARγ KO did not impair
TZD action in a mouse model of insulin resistance [63].
These results raise the question of which tissues are really
necessary to achieve pharmacological action of TZDs. A
precise analysis of PPARγ r e g u l a t i o ni no t h e rt i s s u e sw h e r e
its expression reaches a suﬃcient level could lead to an
answer.
3.In Vitro AnimalStudies
Cytotoxicitystudieshaveshownthatprimaryrathepatocytes
were not more sensitive to TZDs than cells that did not
express the drug metabolizing enzymes involved in their
metabolism. TRO was more toxic than ROSI and PIO at
equimolar concentrations [12]. TRO induced a decline in
mitochondrial transmembrane potential and apoptosis as
well as an oxidative stress. These eﬀects were also observed
in other cell types and on isolated mitochondria [64].
Several studies have been carried out on modulation of
gene expression by TZDs in rodent hepatocytes (Table 1).8 PPAR Research
Diﬀerent concentrations and exposure times have been
tested although a 24h-treatment was the most frequent.
Using Applied Biosystem rat genome survey microarrays
with 26857 probes, Guo et al. [12] compared the eﬀects
of ﬁve PPARγ agonists, including TRO, CIG, ROSI, and
PIO, in rat hepatocytes after a 6-hour treatment. Around 2-
fold more genes were modulated in TRO- and CIG- than
in ROSI- and PIO-treated cell samples. Genes related to
cell death were deregulated only with the most cytotoxic
TRO and CIG concentrations. Similar observations were
reported by Vansant et al. [36]. TRO was also found
to modulate more genes than other glitazones (ROSI,
PIO) at the same concentration, especially genes related to
oxidative stress, DNA repair, and cell death, such as heme
oxygenase 1 (Ho-1), NAD(P)H quinone oxidoreductase
(Nqo), growth arrest DNA-damage-inducible 45 (Gadd45),
FBJ osteosarcoma oncogene (Fos), BCL2-like 11 (Bcl2l11),
and BH3 interacting domain 3 (Bid3). A TRO response
closer to CIG than to the second TZDs generation, ROSI
and PIO, was also found in the C9 rat liver cell line
[36].
As observed in vivo [31], TRO induced expression of
the PPARγ gene [33] and repressed genes related to lipid
metabolism, such as Fasn and Cebp/α,i nc u l t u r e dr a t
hepatocytes [34]. Cyp induction by TZDs was evidenced in
cultured primary rat hepatocytes using RTq-PCR analyses.
Thus Cyp 3a and 2b subfamily genes were increased after
exposure to TRO, ROSI and PIO [35, 36, 65]. Other genes
including multidrug resistance (Mdr) 2 and 3, cadherin and
superoxide dismutase (Sod) 2, were also up-regulated while
Mdr1andorganicaniontransportingpolypeptide8(Oatp8)
were down-regulated [34].
PPARγ2 expression was shown to induce lipid accumu-
lation in the mouse AML12 liver cell line stably expressing
PPARγ2, and several genes known to be overexpressed
in steatotic liver of ob/ob mice were found to be up-
regulated by TRO, such as adipose diﬀerentiation-related
protein (Adrp), Fabp4, Srebp1, Fasn, and Acc by q-PCR
analysis. Lipid accumulation and the lipid droplet protein
were further increased after a 7-day treatment with TRO
[37].
An extensive study of gene expression changes induced
by TZDs has also been performed on the mouse 3T3-L1
adipocyte cells using microarrays and RTq-PCR [9]. Expres-
siongeneproﬁlesobtainedwithTRO,ROSIandPIOtestedat
concentrations that elicited maximum biological eﬀects (i.e.,
20μM for PIO and TRO and 1μM for ROSI) were distinct
but with an overlapping: 94 out of the 326 deregulated
genes were found to be modulated by the three glitazones
after a 24-hour treatment. For example, pepck, pyruvate
dehydrogenase kinase 4 (Pdk4) and c-Cbl-associated protein
(Cap) were activated by the three compounds but with
diﬀerent time-curves, suggesting diﬀerent mechanisms of
gene regulation. Moreover, ROSI and PIO were more potent
than TRO in activating Pepck and Pdk4 and repressing
regulatorofG-proteinsignaling2(Rgs2).Thesedatasupport
theconclusionthatgeneproﬁlechangesinducedbyTZDsare
diﬀerent in liver cells and in adipocytes, in agreement with in
vivo observations.
4.In Vitro HumanLiverCellStudies
Most studies on the eﬀects of TZDs in human liver have been
performed with primary hepatocyte cultures or hepatoma
cell lines. Primary human hepatocytes are recognized as
the most pertinent in vitro model but they exhibit early
phenotypic alterations and their survival does not exceed a
few days in standard culture conditions. Human hepatocytes
have, in addition, a scarce and unpredictable availability and
are characterized by large interdonor functional variability
[66]. Hepatic cell lines were thought to be an alternative but
most of them have lost most of, if not all, their bioactivation
capacity and consequently are of limited interest. In this
regard, the new human hepatoma HepaRG cell line seems as
an exception [67]. HepaRG cells exhibit a capacity of trans-
diﬀerentiation; they undergo morphological and functional
features of liver bipotent progenitor cells after plating and
at subconﬂuence, lose expression of progenitor markers and
diﬀerentiate into either hepatocyte-like or cholangiocyte-
like cells [68]. Diﬀerentiated HepaRG cells possess most
functional activities of primary mature hepatocytes and the
indeﬁnite growth capacity of hepatoma cells [69]. Note-
worthy, they express major cytochromes P450, conjugating
enzymes, and plasma transporters [70].
The mechanism(s) of TZD hepatotoxicity in humans
still remain(s) controversial. Several proposals have been
advanced to explain the induction of apoptosis by TRO
namelyaccumulationoftoxicmetabolitesorbileacids,mito-
chondrialdamage,andoxidativestress.TROhasbeenshown
to be metabolized by CYP3A4 (the homolog of Cyp3a1 in
rodent) to a very active quinone metabolite which is able
t op r o d u c er e a c t i v eo x y g e ns p e c i e sv i at h er e d o x / c y c l i n go r
to bind to cellular proteins [40]. This CYP3A4-mediated
metabolism is in accordance with the frequent occurrence of
centrilobular necrosis of the liver. CYP3A4 is also induced
by TRO in primary human hepatocytes [71, 72]a n da
correlation has been observed between CYP3A4 levels and
hepatocyte sensitivity to glitazone [73].
Studies dealing with the eﬀects of TZDs on gene expres-
sion in either primary human hepatocyte cultures or human
hepatoma cell lines are scarce and most of them studied
only few genes [76, 79]( Table 2). Human hepatocytes were
slightly more sensitive than their rat counterparts [34],
but less sensitive than human hepatoma HepG2 cells to
cytotoxicity induced by TRO, supporting the conclusion
of an absence of correlation between TRO toxicity and its
hepaticmetabolism.TROwasfoundtoinducecellarrestand
to cause time- and concentration-dependent apoptosis in
v a r i o u sl i v e rc e l lt y p e s[ 75, 77, 83]. Cell arrest was associated
with increased expression of a cascade of cyclin-dependent
kinase inhibitors, that is, cdki p21, p27, and p18 that each
plays a crucial role in adipocyte diﬀerentiation through
PPARγ activation [81]. This increase occurred through
down-regulation of nuclear S-phase kinase-associated pro-
tein 2 (SKP2) [80]. Apoptosis was associated with activation
of both c-Jun N-terminal protein kinase and p38 kinase and
overexpression of proapoptotic proteins and cyclooxygenase
2(CO X-2)[77,83].Theseeﬀectsarenotlimitedtohepatoma
cell lines. Indeed, TRO also induced growth arrestof prostatePPAR Research 9
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Figure 1: Two-dimensional hierarchical clustering of gene expression proﬁles induced by TRO treatment in primary human hepatocytes
from ﬁve donors and HepaRG cells. The clustering was generated by using the Resolver system software with an agglomerative algorithm,
the Ward’s min variance link heuristic criteria, and the Euclidean distance metric. Cultures and microarray analysis as in Table 2.
and bladder carcinoma cell lines [84]. By contrast, other
members of the glitazone family, ROSI or PIO, had no eﬀect
on the growth of these cell lines [84] and did not cause
any apoptosis of HepG2 cells [83]. The endogenous ligand
15-deoxy-prostaglandin J2 was also found to inhibit growth
of prostate and bladder carcinoma cell lines by inducing
apoptosis [84]. Since these eﬀects are selective of the PPARγ
ligand and the cell line, they can be interpreted as PPARγ-
independent eﬀects [84]. Apoptosis induced by TRO in
human MCF-7 breast carcinoma cells has been associated
with induction of GADD45 gene expression [85] while
growth inhibition has been correlated to overexpression of
another DNA damage gene, GADD153, in nonsmall lung
carcinoma cells [86].
As observed in rat hepatocytes, Kier and coworkers
[87] showed that TRO induced more genes than ROSI in
human hepatocytes. This observation was based on analysis
of gene expression proﬁles and did not include individual
characterization of deregulated genes. Other studies have
shown a down-regulation of SREBP-2, a gene encoding the
sterol regulatory element-binding protein-2 that mediates
cholesterol synthesis, as well as the two SREBP-2 target
genes, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
(HMGCR) and low density lipoprotein receptor (LDLR),
in HepG2 cells exposed to 30μMT R Of o r4 h[ 78].
In agreement with in vivo human data, TZDs were also
found to modulate CYP activities in human hepatocyte
cultures. CYP3A4 and CYP2B6 were induced by TRO [34]
and only CYP2B6 by ROSI and PIO [35] in primary human
hepatocytes. Similar observations were made in the well-
diﬀerentiated HepaRG cell line [74].
Up to now, studies on human hepatocytes have been
limited to a few donors (one to three), and no interdonor
variability has been considered. Since interdonor variability
in response to chemical inducers or inhibitors is well
established, we recently compared the eﬀects of TRO in
human hepatocyte cultures from ﬁve donors after a 24-
hour treatment using pangenomic microarrays (Rogue et
al., unpublished data). Two-dimensional hierarchical clus-
tering of gene expression proﬁles showed that hepatocyte
populations separated according to the donor and not to
the TRO concentration (Figure 1). It exhibited two separate
clusters: one with donors 4 and 5 and the second with
donors 1, 2, and 3. The number of genes modulated by
TRO greatly varied as a function of the donor and drug
concentration. At 5 and 20μM, TRO modulated 5754 and
7266 genes, respectively, in at least one donor but only 4 and
29 genes in the 5 donors, respectively (Figure 2). The small
subset of common deregulated genes in hepatocyte cultures
from several donors is in agreement with the ﬁndings12 PPAR Research
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Figure 2 :T o t a lg e n en u m b e r sm o d u l a t e db y5a n d2 0μMT R Oi n
primaryhumanhepatocytesfromonetoﬁvedonors(FC ≥ 1.5pv≤
0.01). Cultures and microarray analysis as in Table 2.
reported by Goyak et al. [88], showing that the number of
modulated genes deregulated in ten populations of human
hepatocytesbyarochlor1254,di(2-ethylhexyl)phthalate,and
phenobarbital did not exceed 0.1%. In our study, among
the few genes deregulated in the ﬁve donors by 5μMT R O ,
only two genes involved in oxidative stress, namely, mannose
binding lectin 2 (MBL2) and serum/glucocorticoid regulated
kinase 2 (SGK2), were induced. Genes involved in lipid
metabolism, such as FABP1 were deregulated only by 20μM
TRO in all the donors. Several PPAR target genes, such
as CYP4A1, CPT1, or CD36, were induced in the two
hepatocyte cultures treated by 40μMT R O .
Despite its therapeutic indications, TRO only slightly
aﬀected transcription of genes involved in glucose home-
ostasis. Fructose-1,6-bisphosphatase 1 (FBP1), an enzyme
involvedingluconeogenesis,wasnotmodulatedinanyofthe
ﬁve donors, in agreement with previous observations [34]
while PDK4 and PEPCK were diﬀerently regulated across
the donors. Their transcription could be either induced,
repressed, or not aﬀected by TRO treatment.
Comparison of gene proﬁles after TRO treatment in ﬁve
human hepatocyte populations and the well-diﬀerentiated
human hepatoma HepaRG cells evidenced a clear separation
betweenthetwocellmodelsbytwo-dimensionalhierarchical
clustering. HepaRG cell samples separated as a function of
TRO concentration and the dendrogram showed that they
were closer to donors 4 and 5 than to donors 1, 2, and
3. The number of commonly modulated genes between
HepaRG cells and primary human hepatocytes increased
with the drug concentration; it was higher than the number
of commonly modulated genes in four out of ﬁve donors.
Among them, genes involved in lipid metabolism, such as
FABP4 or CD36, were induced. Taken altogether our data
support the view that the eﬀects induced by TRO and more
generally by PPARγ agonists are quite variable from one
individual to another. This could explain the occurrence of
toxic eﬀects in only few treated patients. However, whether it
would be possible to predict their potential hepatotoxicity in
some patients on the basis of analysis of the expression level
of a peculiar gene subset requires further studies.
5. Conclusions
Despite the numerous published studies on TZDs, their
pharmacological and toxicological eﬀects still remain
obscure. Adipose tissue seems to be a predominant target
organ. However, achievement of TZD pharmacological eﬃ-
ciency is obtained not only through an adipose-mediated
mechanism but also requires an action in other organs,
notably liver and skeletal muscle and also, as recently
reported, in macrophages [58]. Moreover, PPARγ itself is
required in a majority of metabolic tissues for regulation of
insulin action and normal physiologic response to nutrients
and it plays a critical role in the development of steatosis.
The determinants of susceptibility to glitazone-induced
idiosyncratic hepatotoxicity remain to be elucidated. Studies
have mainly concerned the most cytotoxic compound TRO.
Evidence has been provided that toxicity is not directly
related to its metabolism and the generation of a quinone
metabolite. Direct toxicity caused by mitochondrial dys-
function has been demonstrated using both hepatic and
nonhepatic in vitro models. Whether hepatotoxic eﬀects of
TZDs are related to PPARγ activation is not clear. PPARγ is
only poorly expressed in the liver and both dependent and
independent eﬀects of glitazones have been seen.
Most in vitro studies have been performed with TRO
concentrations of 50μM or more while maximum plasma
concentrations reached 3 to 6μM in humans, making
questionable the extrapolation of in vitro data to the in vivo
situation. In comparison to TRO, ROSI is less toxic. The
daily dose necessary for TRO therapeutic eﬃcacy was 200 to
600mg/daywhileitisonly4to8mg/dayforROSI,indicating
that patients were exposed to quite diﬀerent doses between
the ﬁrst and second generations of TZDs [89].
During the last years, some studies have been designed
to identify potential hepatic target genes in in vivo and in
vitro models using RT-qPCR and microarray technologies.
The amount of available data is still limited and has been
obtained from diﬀerent experimental conditions. However,
some genes have been found to be usually modulated, being
mainly related to drug and lipid metabolism. Interestingly,
we have observed massive interindividual variability in the
response of primary human hepatocytes to TRO treatment
that could reﬂect the human situation. However, much more
work is needed in order to identify the more pertinent genes
which are diﬀerently expressed in the human hepatocyte
populations and to determine whether the most critical
eﬀects in the liver are dependent or not on PPARγ activation.
Moreover, it would be important to estimate the eﬀects
resulting from long-term repeated glitazone treatments and
todetermineifintracellularPPARγ levelsinhumanlivercells
are a critical parameter. The possible long-term treatmentsPPAR Research 13
of diﬀerentiated normal and steatotic human hepatoma
HepaRG cells could represent a unique way to better
understand hepatotoxicity of PPARγ agonists.
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